Vistusertib, also known as AZD2014, is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD2014 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.
Related Prodcuts:
Tacrolimus; AZD8055; AZD8055 fumarate; OSI-027; Zotarolimus; XL388; INK 128; PP121; Desmethyl-VS-5584; AZD-8055